MSD

News

Scotland first in Europe to back MSD drug for VHL tumours

Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic

Oncology

An oncology workforce fit for the future

To continue delivering high-quality and patient-centred care, the future oncology workforce of the NHS needs to be agile, expansive, and diverse.

News

One in five men carries HPV linked to cancer

Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

Scotland first in Europe to back MSD drug for VHL tumours

An oncology workforce fit for the future

One in five men carries HPV linked to cancer

Keytruda backed for 'basket' of new cancers via NHS

FDA clears J&J's 2-in-1 tablet for prostate cancer

MSD, Moderna start phase 3 trial of mRNA cancer jab

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks